Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 5,250 shares at $6.55 ($35K) on 2014-07-25, disclosed to the SEC on 2014-07-25.
Scheduled sale ($35k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.88 | 1,700 | $12K | 33.0% |
| 2 | $6.81 | 1,850 | $13K | 35.6% |
| 3 | $6.55 | 1,700 | $11K | 31.4% |
| Total | $6.75 avg | 5,250 | $35K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |